logikomm.com
Powered By
Neublastin Enters Phase I Clinical Development As A Novel Treatment For Neuropathic Pain (Medical News Today)
Published: NsGene A/S announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field of peripheral nervous system disorders, has entered into Phase I clinical development for the treatment of neuropathic pain. The first patient in the Phase I trial has been dosed at the University of Adelaide in Australia....
Read More...
More Articles
News Headlines
Neublastin Enters Phase I Clinical Deve...Published:Sun, 06 Sep 2009 10:15:24 GMT NsGene A/S announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field of peripheral nervous system disord......
Emirati service management Khidmah comp...Published:Sun, 06 Sep 2009 08:47:05 GMT Khidmah LLC, the first Emirati owned and operated services management company in Abu Dhabi, today announced the completion of leasing for all 588 villas in the Sorouh Development,......
Delhi to put details of legislators' de...Published:Fri, 04 Sep 2009 16:27:26 GMT The Central Information Commission (CIC) has directed the Delhi government to put up information on the utilisation of the legislators' development funds on its website.......
Karolinska Development Portfolio Compan...Published:Sat, 05 Sep 2009 11:15:18 GMT Karolinska Development (publ) announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug s......
NOXXON Is Awarded Research And Developm...Published:Sun, 06 Sep 2009 10:14:34 GMT NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced that the company......
del.icio.us
| 
Digg
| 
Reddit
|
